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Application of Indomethacin in Medicine and Pharmacy
Indomethacin, a non-steroid anti-inflammatory drug (NSAID), has been used in different spheres of medicine since the 1960s. It is successfully 
administered as an anti-inflammatory and pain-relieving medication in rheumatoid and other diseases. According to recent research, indometha-
cin may become a promising drug enhancing endogenous remyelination in patients with multiple sclerosis. Also, indomethacin affects cell prolif-
eration and invasion, thus it is used to manage pancreatic cancer in patients with hyperglycemia. In addition, indomethacin can inhibit protein 
synthesis in colorectal carcinoma and other types of cancer cells. The article reviews modern indomethacin medications and the different dosage 
forms on the Russian pharmaceutical market. Indomethacin poor water solubility is one of the reasons for decreasing its biopharmaceutical char-
acteristics. According to the conducted research, a prospective way to improve indomethacin solubility and bioavailability is the Solid Dispersion 
(SD) method. SDs are bi- or multicomponent systems consisting of the drug and the carrier. They are a highly dispersed solid phase of the drug or 
molecular-dispersed solid solutions with a partial formation of a variable composition complex and a carrier. The article provides a brief overview 
on different aspects of obtaining, investigating, and applying indomethacin SDs with various polymers.
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Аспекты применения индометацина
в медицине и фармации
Синтезированный в шестидесятых годах прошлого столетия типичный представитель класса нестероидных противовоспалительных 
средств индометацин нашел широкое применение в различных областях медицины. Сочетание противовоспалительного и обезболива-
ющего действия обусловило успешное применение индометацина при ревматических заболеваниях. Новейшие исследования выявили, 
что препарат может стать перспективным средством и в терапии ряда иных патологий. В статье приведен краткий обзор ассорти-
мента современных препаратов и различных лекарственных форм индометацина на отечественном фармацевтическом рынке. Одним 
из факторов, снижающих биофармацевтические характеристики препаратов индометацина, является его малая растворимость 
в воде. Согласно результатам анализа литературных данных, одной из перспективных технологий, способных успешно увеличить рас-
творимость и биодоступность индометацина, является метод получения его твердых дисперсий. Твердые дисперсии ― это би- или 
многокомпонентные системы из лекарственного вещества и носителя, представляющие собой высокодиспергированную твердую фазу 
лекарственного вещества или молекулярно-дисперсные твердые или жидкие растворы с частичным образованием комплексов перемен-
ного состава с материалом носителя. Представлен краткий обзор работ, посвященных различным аспектам получения, исследования 
и применения твердых дисперсий индометацина с разными полимерами-носителями. 
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Introduction
Indomethacin is one of the most widely used NSAIDs in 
modern medicine. T.Y. Shen et al. synthesized indomethacin at 
Merck, Sharp and Dome laboratory, New York. The medica-
tion’s chemical properties and production method were first de-
scribed in 1963. A lot of clinical trials were conducted thereafter 
which highlighted advantages of indomethacin over pyrazolone 
derivatives (amidopyrine and phenylbutazone) and salicylates 
(Aspirin) [1]. Combined administration of indomethacin and 
steroid drugs was proved to enhance the effect of the latter. Due 
to anti-inflammatory and pain relieving effects, indomethacin 
was successfully used in rheumatoid diseases such as rheumatoid 
arthritis, osteoarthritis, arthritic gout, and ankylosing spondyli-
tis. Indomethacin was the first nonsteroidal drug which ensured 
consistent reduction of joint swelling in rheumatoid arthritis. 
Moreover, it became the drug of choice in arthritic gout. Com-
monly reported side effects of indomethacin include headache, 
dizziness, asthenia, and dyspepsia. Due to therapeutic benefits 
indomethacin has become the gold standard of NSAIDs.
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Indomethacin is a synthetic nonsteroidal indole derivative 
2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetic 
acid (Fig.).
According to drug physical properties, indomethacin 
is white to pale-yellow odorless crystalline powder [2, 3]. 
Crystals exhibit polymorphism with one form of polymor-
phic crystals melting at about 155 °C and the other at about 
162 °C, respectively [3]. Indomethacin is soluble in ether, ac-
etone and castor oil; sparingly soluble in ethanol, practically 
insoluble in water (0.937 mg/L at 25 °C) which limits its ap-
plication in pharmaceutical technology and decreases some 
parameters of its dosage forms. The medication is stable in 
neutral or slightly acidic media and is decomposed by strong 
alkali [2]; stored at temperature below 25 °C away from light 
and moisture [2, 3].
Indomethacin is one of the most active NSAIDs [4]. Its 
pharmacological activity includes nonselective inhibition of 
the enzyme cyclooxygenase (COX) and partial blocking of 
prostaglandin biosynthesis thus providing anti-inflammatory, 
analgesic, and antipyretic effects. The inhibition of COX-1 
leads to suppression of thromboxane A2 synthesis which results 
in reversible reduction of platelet aggregation [3].
Indomethacin dosage forms are widely used in different 
areas of medicine. The drug is systemically administered in 
inflammatory and degenerative musculoskeletal diseases (ar-
ticular syndrome, spine pain, traumatic inflammation of soft 
tissues and joints, rheumatism), pain syndrome (head and 
toothache, myalgia, neuralgia, pain after trauma and surgery 
accompanied with inflammation). In cases when potential 
benefits outweigh side effects, the drug is prescribed in algo-
dismenorrhea, inflammatory processes in the small pelvis, 
pericarditis, and in premature birth. It is used as an adjuvant 
in ENT disorders with acute pain syndrome. Also, it is applied 
topically in ligament, tendon, muscle and joint inflammation 
after traumas. In ophthalmology indomethacin is prescribed to 
inhibit myosis in cataract surgery, inflammation after surgery, 
and noninfectious conjunctivitis. In dentistry it is administered 
in arthritis and arthrosis of the temporomandibular joint and 
oral tissues inflammatory disorders [3].
According to recent research, indomethacin may become 
a promising drug improving endogenous remyelination in 
patients with multiple sclerosis. It can cross the blood-brain 
barrier and stimulate oligodendrocytes formation from their 
progenitor cells [5]. Via up-regulating E-cadherin, coded by 
CDH1 gene suppressor [6], indomethacin affects cell prolifera-
tion and invasion, thus it is used to manage pancreatic cancer in 
patients with hyperglycemia [7].
Due to its ability to selectively activate the double-
stranded RNA-dependent protein kinase and cause rapid 
phosphorylation of eIF2α, Indomethacin can inhibit protein 
synthesis in colorectal carcinoma and other types of cancer 
cells, which makes it a promising drug in cancer manage-
ment [8].
Indomethacin Preparations
Ten brand names of indomethacin are currently available 
on the Russian pharmaceutical market. They are as follows: 
Indomethacin, Indobene, Indocollyre, Indomethacin 100 
Berlin-Chemie, Indomethacin 50 Berlin-Chemie, Indometha-
cin Sopharma, Indomethacin-Akri, Indomethacin-Altpharm, 
Indomethacin-Biosintez, and Metindol Retard. Most Indo-
methacin dosage forms are manufactured by the following 
Russian companies: JSC Murom Apparatus Producing Plant, 
OJSC Biosintez, OOO (a limited liability company under 
the laws of Russian Federation) Ozon, JSC Pharmaceutical 
Factory Obolenskoe, Akrikhin, and OOO Altpharm. Foreign 
Indomethacin preparations are produced in Germany (Merkle 
GmbH., Berlin-Chemie AG), France (Laboratoire Chauvin 
SA), Poland (ICN Polfa RzeszÓw SA), Bulgaria (Sopharma 
AD, Balkanpharma Dupnica AD, Balkanpharma Troyan AD, 
VetProm AD), Belarus (Borisovskiy Zavod Medicinskikh Pre-
paratov OJSC), Moldova (Farmaprim).
Pharmaceutical substances to produce indomethacin prep-
arations are manufactured in China (Taicang Pharmaceuti-
cal Company, CSPC Pharmaceutical Group Limited, Shiji-
azhuang GroupZhongnuo Pharma Co., Ltd.).
Indomethacin is administered orally, intramuscularly, rec-
tally, and locally. The initial adult dose prescribed orally after 
meals is 25 mg 2−3 times a day. Then a daily dose is increased 
to 100–150 mg (3−4 times a day) depending on the drug toler-
ance. 75 mg (1 capsule) of indomethacin retard is taken once or 
twice daily (in the morning and in the evening) 5−10 days, then 
1 capsule a day in the evening [4].
The brand name of coated tablets manufactured by the 
Russian company OJSC Biosintez is Indomethacin-Biosintez. 
Enteric coated tablets are Indomethacin (Russia, Bulgaria) 
and Indomethacin Sopharma (Bulgaria). Prolonged release 
tablets are Metindol Retard (Poland) [2]. Effervescent tablets 
containing indomethacin, caffeine and prochlorperazine to 
treat headache are manufactured by E-Pharma Trento S.P.A. 
(Italy) but they are not registered in Russia. Rectal sup-
positories of 50 mg or 100 mg are administered twice daily 
[4]. They are Indomethacin-Altpharm by OOO Altpharm and 
indomethacin manufactured by Farmaprim and OJSC Bio-
sintez. Also, foreign companies produce rectal suppositories 
under the following brand names: Indomethacin (Croatia and 
Moldova), Indomethacin 100 Berlin-Chemie, Indometha-
cin 50 Berlin-Chemie (Germany), Indomethacin Sopharma 
(Bulgaria) [2]. To treat acute conditions, indomethacin is 
administered intramuscularly ― 60 mg once or twice daily for 
7−14 days followed by tablets or suppositories. Indomethacin 
ointment is applied topically in acute and chronic polyarthritis, 
neuritis, plexitis, radiculitis, thrombophlebitis and arthropathic 
psoriasis. The total daily amount should not exceed a 15 cm 
length of ointment squeezed from the tube for adults and 7.5 
cm for children [4]. Indomethacin 10% ointment is produced 
by national factories JSC Murom Apparatus Producing Plant, 
OJSC Biosintez, OOO Ozon and foreign companies (Belarus, 
Bulgaria). Indomethacin-Akri, Indomethacin-Biosintez, and 
Indomethacin Sopharma 10% ointment are manufactured by 
the Russian companies Akrikhin, OJSC Biosintez, and Bulgar-
ian Sopharma AD, respectively.
Indomethacin gel is represented by a German medication 
Indobene (1%) and by a Bulgarian preparation Indomethacin 
(5% and 10%) [2]. Eftimethacyn, the ointment produced by 
the Russian company Medic LDF and containing amino-
phylline, diphenhydramine, and indomethacin, is used to 
treat diseases of the musculoskeletal system. Gel containing 
indomethacin and angioprotector troxerutin is manufactured 
in Bulgaria by VetProm AD, Balkanpharma Troyan AD under 
Fig. Indomethacin. Molecular weight 357.793 g/mol
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the brand names Troximethacin and Indovasin, respectively. 
These medications are used in combination therapy in chronic 
venous insufficiency of lower limbs, superficial thrombophlebi-
tis, rheumatoid lesions of soft tissues, and postsurgical edemas. 
In ophthalmology indomethacin drops are administered in 
noninfectious inflammatory processes, e.g. after surgery [4]. 
Ophthalmological medications include eye drops Indocollyre 
produced in France.
Despite its wide application and high efficacy, indometha-
cin has pronounced side effects which is critical to widespread 
administration. The main mechanism of NSAIDs side effects 
lies in the main therapeutic mechanism. The medications in-
hibit the synthesis of protective specific prostaglandins in the 
mucous layer of the gastrointestinal tract (GIT) which leads 
to peptic ulcerative lesions of the stomach and the duodenum. 
According to endoscopic studies, such adverse events occur in 
10–20% of patients administered NSAIDs on a regular basis. 
Along with the risk of arterial hypertension, bronchospasms, 
toxic hepatitis, thrombopenia, cardiac rhythm disorders, 
indomethacin negatively affects the GIT [2, 4] which is typi-
cal for patients receiving the most commonly prescribed oral 
dosage form. Side effects include nausea, vomiting, pain in 
the epigastrium, erosive ulcerative lesions of the GIT, gastro-
intestinal and rectal bleeding. Thus, indomethacin has a wide 
range of contraindications, including erosive ulcerative lesions 
of the GIT and some forms of enterocolitis [9]. To prevent 
and decrease dyspeptic disorders, indomethacin should be 
taken with milk during or after meals along with antacids. The 
medication is contraindicated in bronchial asthma, thrombo-
penia, and renal insufficiency; should not be administered in 
pregnant women because of its teratogenic action [4]. Another 
drug disadvantage is its low water solubility which decreases 
its BA. It requires high-dose intake which increases the risk 
of side effects [9]. Similar to other anti-inflammatory drugs, 
indomethacin is a drug of long term administration and its 
anticipatory discontinuation may lead to disease recurrence 
which highlights the necessity for dose decrease in terms of 
safe intake.
There are different dosage forms of indomethacin. They are 
tablets of 5, 10, and 25 mg (N. 10, 30, 50); prolonged release 
tablets of 75 mg (N. 25, 50); pills of 25 mg (N. 30); capsules of 
25, 30, and 50 mg (N. 20, 30, 50); capsules retard of 75 mg (N. 
10, 50); rectal suppositories of 50 and 100 mg (N. 5, 10); 3% in-
jection solution in 2 ml ampules; 1% and 10% gel in 50 and 100 
gr tubes; 5% and 10% ointment in 30 and 40 gr tubes; 0.1% and 
1% eye suspension; 0.1% eye drops. Shelf life of indomethacin-
containing drugs varies according to the manufacturer and dos-
age form: tablets can be stored from 3 to 5 years, capsules ― 4.5 
years, ointment and gel ― from 2 to 3 years, suppositories ― 3 
years, eye suspension ― 2 years [4], eye drops ― 1.5 years. 
Rectal suppositories, 10% ointment, enteric coated tablets and 
coated tablets are produced in Russia, while gel, eye drops and 
prolonged release tablets are manufactured by foreign compa-
nies only. Pills, capsules, injection solution and eye suspension 
of indomethacin are not presented on the Russian market as 
state license is expired.
Indomethacin dosage forms
with improved solubility
The issue of drug solubility improvment is one of interest 
for the current research which stresses the importance and 
timeliness of improving and designing Indomethacin-contain-
ing drugs. Many studies focused on the ways for reducing indo-
methacin side effects. Different micro- and nanocarriers based 
on biodegradable polymers have been developed. Microencap-
sulation of indomethacin into biodegradable particles of poly-
lactide-glycolide and its copolymer polylactide-polyethelene 
glycole using compressed CO2 allowed getting sustained release 
of the model drug [10]. Desired compositions of indomethacin 
sustained release microcapsules using ethyl cellulose, hydroxy 
propyl methyl cellulose, and chitosan-carboxymethyl-cellulose 
are described [11].
A pharmaceutical composition of indomethacin encapsu-
lated in phospholipid nanoparticles with increased antirheu-
matoid and anti-inflammatory activity when taken orally and 
intravenously was designed and patented by Russian scientists 
in 2011. When administered to rats orally, indomethacin BA 
increased two-fold compared to the drug in its free form [9, 12]. 
A pharmaceutical composition of indomethacin encapsulated 
in phospholipid nanoparticles patented in 2012 is one of the 
up-to-date developments in ophthalmology [13].
Another study concerning the production of poly (vinyl 
acetate) nanoparticles with indomethacin incorporated in them 
to include in ophthalmic formulations describes a sustained 
release dosage form [14]. A group of scientists from China 
synthesized mesoporous silica nanospheres functionalized with 
aminopropyl groups which include the drug coated with a 
natural organic polymer alginate (ALG). Sustained release of 
indomethacin was mainly due to the blockage effect of the 
coated ALG [15]. Ways to form indomethacin microspheres 
using natural and synthetic polymers (albumin, ethyl cellulose 
and Eudragit L100) are described [16].
One more study focused on the emulgel system of indo-
methacin using 2 types of gelling agents: Carbopol 934 and 
Xanthan Gum which has higher drug release and desired physi-
cal properties (color, homogeneity, consistency, spreadability, 
pH value) [17].
To solve the problem of indomethacin poor solubility, a 
promising approach to advance the technology of drug forma-
tion and increase BA ― SD method ― was used. SDs are 
bi- or multicomponent systems consisting of the drug and the 
carrier. They are a highly dispersed solid phase of the drug or 
molecular-dispersed solid solutions with a partial formation of 
a variable composition complex and a carrier [18, 19]. Russian 
and foreign studies on Indomethacin solubility improvement 
with polymers such as hydroxy propyl methyl cellulose, Solup-
lus, polyvinyl acetate, polyethelene glycol (PEG), and polyvi-
nylpyrrolidone (PVP) of different molecular weights were used 
to produce SD [9, 20].
Another study analyzed the drug permeability across 
Caco-2 monolayers and revealed that the drug absorption 
increased four-fold when reformulated as SD with hydrophilic 
PEG 8000 compared to the drug in its free form. It may be ex-
plained by transition of the drug from the crystalline to amor-
phous state upon dispersing within PEG matrix. The study 
demonstrated no chemical interaction between the drug and 
the carrier [20]. The research stated that SD method greatly 
influences the stability of the drug amorphous state and the 
drug concentration in the solution. The polymers added as 
pre-dissolved solutions generated higher supersaturation con-
centrations of the drug. In contrast, SDs maintained super-
saturation for longer [21].
Prospects
of Indomethacin Solid Dispersion
Many years have passed and a lot of research has been 
done since indomethacin was synthesized and introduced 
in clinical practice. Thus, all pharmacological and techno-
logical aspects of its implementation have been thoroughly 
studied. The chemical substance indomethacin is an active 
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agent widely used in various dosage forms: tablets, prolonged 
release, capsules retard, rectal suppositories, ointment, and 
eye drops. 
The substance may seem to have lost its innovative po-
tential. However, this opinion is inaccurate. Scientists of the 
I.M. Sechenov First Moscow State Medical University have 
been conducting research to enhance bioavailability of poorly 
water soluble drugs by means of the solid dispersion method, 
using polymer carriers for many years. This approach has been 
used to investigate over 30 poorly water soluble substances 
from different pharmacological groups for the last 15 years 
[18, 22−25]. 
The solid dispersion method allows improving biophar-
maceutical characteristics of substances including solubility 
improvment. Therefore, it enables us to widen the scope of 
the newly synthesized and well-known substances application 
enhancing bioavailability and reducing side effects. 
Modern research in Russia aims at developing innovative 
dosage forms with advanced pharmaceutical characteris-
tics, containing indomethacin solid dispersion which may 




Indomethacin is one of the most active NSAIDs used as an 
antipyretic, pain relieving, and analgesic medication. There is 
a wide range of dosage forms both national and foreign on the 
pharmaceutical market in the Russian Federation. However, 
the substance is poorly water soluble and has a number of side 
effects. SD method to increase indomethacin solubility and 
dosage forms design is a pressing issue in modern pharmacy. 
Therefore, the Federal State Autonomous Educational Institu-
tion of Higher Education I.M. Sechenov First Moscow State 
Medical University of the Healthcare Ministry of the Russian 
Federation conducts detailed research to produce indometha-
cin SDs with polymers to enhance its solubility which enables 
to further develop highly soluble dosage forms with enhanced 
BA and reduced side effects.
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